Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by barackon Oct 30, 2012 11:29am

120 Views

Post# 20539296

RE: RE: RE: Money coming in more on the way. Wher

Can anyone find me a boitech/pharma stock with 3 FDA approved drugs that's as cheap as DND. Absorica can be a best in cass drug with an existing ~$500 million US market.

this is a very well managed company with a strong and growing balance sheet.

Lots of upside.

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports